title: Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.
authors.forename: U
authors.initials: U
authors.lastname: Bacher
authors.forename: W
authors.initials: W
authors.lastname: Kern
authors.forename: T
authors.initials: T
authors.lastname: Alpermann
authors.forename: S
authors.initials: S
authors.lastname: Schnittger
authors.forename: A
authors.initials: A
authors.lastname: Kohlmann
authors.forename: H-U
authors.initials: HU
authors.lastname: Klein
authors.forename: M
authors.initials: M
authors.lastname: Dugas
authors.forename: C
authors.initials: C
authors.lastname: Haferlach
authors.forename: T
authors.initials: T
authors.lastname: Haferlach
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001752:Blast Crisis / Q000473:pathology*; D003582:Cytogenetics; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000235:genetics / Q000401:mortality / Q000473:pathology; D009687:Nuclear Proteins / Q000235:genetics; D000090243:Nucleophosmin; D011379:Prognosis
chemical_list: D009687:Nuclear Proteins; D000090243:Nucleophosmin